ReviewTherapeutic advances in medical oncology2017
Refractory carcinoid syndrome: a review of treatment options.
Review in Therapeutic advances in medical oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04831567 (Phase II Study of MIBG-I131), which is not on this map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase II Study of MIBG-I131 (Metaiodobenzylguanidine) in Patients With Well Differentiated Neuroendocrine Tumors and MIBG Positive Scan
Who cites it
31 citing papers in PubMed, 66 citations in OpenAlex.
- TELEPRO: Patient-Reported Carcinoid Syndrome Symptom Improvement Following Initiation of Telotristat Ethyl in the Real World.The oncologist · 2019Trial
- An Update on Novel Pharmacotherapies for the Treatment of Neuroendocrine Tumors.International journal of molecular sciences · 2025Review
- Red Emitting Fluorescent EuDPA Complex as a Probe for the Detection of Serotonin, A Neurotransmitter.Journal of fluorescence · 2025Article
- Octreotide infusion pump in patients with functional neuroendocrine tumors and refractory hormonal syndrome.Endocrine oncology (Bristol, England) · 2025Article
- Anesthetic key points in a patient with a terminal ileum neuroendocrine tumor and a rare carcinoid left heart disease presented for non-cardiac surgery: case report.BMC anesthesiology · 2024Article
- The Role of Somatostatin Analogues in the Control of Diarrhea and Flushing as Markers of Carcinoid Syndrome: A Systematic Review and Meta-Analysis.Journal of personalized medicine · 2023Review
- 60-year-old Female with Edema.Clinical practice and cases in emergency medicine · 2022Article
- European Neuroendocrine Tumor Society (ENETS) 2022 Guidance Paper for Carcinoid Syndrome and Carcinoid Heart Disease.Journal of neuroendocrinology · 2022Article
- Sex differences in carcinoid syndrome: A gap to be closed.Reviews in endocrine & metabolic disorders · 2022Review
- Real-World Clinical and Patient-Reported Outcomes from the Longitudinal Telotristat Ethyl Treatment Registry of Patients with Neuroendocrine Tumors.Cancer management and research · 2022Article
- Antiproliferative Systemic Therapies for Metastatic Small Bowel Neuroendocrine Tumours.Current treatment options in oncology · 2021Review
- How I treat neuroendocrine tumours.ESMO open · 2020Review
- A Budget Impact Model of the Addition of Telotristat Ethyl Treatment to the Standard of Care in Patients with Uncontrolled Carcinoid Syndrome.PharmacoEconomics · 2020Article
- Role of Somatostatin in the Regulation of Central and Peripheral Factors of Satiety and Obesity.International journal of molecular sciences · 2020Review
- Management of Diarrhea in Patients With Carcinoid Syndrome.Pancreas · 2019Article
- Medical record review of transition to lanreotide following octreotide for neuroendocrine tumors.Journal of gastrointestinal oncology · 2019Article
- Evidence-Based Policy in Practice: Management of Carcinoid Syndrome Diarrhea.P & T : a peer-reviewed journal for formulary management · 2019Article
- Nutritional and vitamin status in patients with neuroendocrine neoplasms.World journal of gastroenterology · 2019Review
- Article
- Carcinoid heart disease involving the left heart: a case report and biomarker analysis.ESC heart failure · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Carcinoid syndrome (CSy) is a constellation of symptoms that may commonly present in patients with well differentiated neuroendocrine tumors (NETs), with somatostatin analogs (SSAs) being the first-line option for symptom management. However, symptomatic progression eventually occurs and in this scenario of a refractory CSy; several treatment options have been studied such as dose escalation of SSA, interferon and liver-directed therapies. Nevertheless, recent phase III trials have contributed to the understanding and management of this condition. We performed a comprehensive review of interventional studies examining refractory CSy to provide the evidence for current treatment options and propose a treatment sequence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.